Oncolytics Biotech (ONCY) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Nebius shares sink on CoreWeave's bond yield spike and insider sales
- IonQ prices $2 billion equity offering at $40 per share
- Rocket Lab delays Neutron rocket debut to 2027
- Bloom Energy stock falls as inflation data pressures markets
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
May 9, 2024 4:01 PM EDTPelareorep advancing to registration-enabling studies
Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer
Overall survival data from BRACELET-1 breast cancer study expected in H2 2024
Cash position of $29.6 million provides runway through critical milestones into 2025
Management hosting conference call and webcast today at 4:30 p.m. ET
SAN DIEGO and CALGARY, AB,... More



